Form 4: Definium Therapeutics CLO Sells Shares for Tax Obligations

Definium Therapeutics' Chief Legal Officer, Mark Sullivan, sold 10,702 common shares at a weighted average price of $18.47 to cover tax obligations from vested restricted stock units.

Summary

• Mark Sullivan, Chief Legal Officer of Definium Therapeutics, Inc., sold 10,702 common shares.
• The sale occurred on March 25, 2026, at a weighted average price of $18.47 per share, with prices ranging from $18.36 to $18.80.
• The transaction was executed to satisfy withholding tax obligations related to the settlement of vested restricted stock units.
• The sale was conducted under a pre-arranged Rule 10b5-1 plan adopted on March 14, 2024.
• Following the transaction, Mr. Sullivan beneficially owns 271,079 common shares.
• The amount of shares beneficially owned includes 793 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was for tax purposes under a pre-arranged plan, which is a common and expected occurrence for executives receiving equity compensation and does not reflect a change in company fundamentals or management's outlook.

Future Outlook

No specific future outlook or guidance is provided in this insider transaction report.

Management Comments

• The reported shares were sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024.

Industry Context

StockSavvy.ai notes that sell-to-cover transactions for tax obligations are a common and routine occurrence for executives receiving equity compensation. These transactions are frequently pre-arranged under Rule 10b5-1 plans to ensure compliance with insider trading regulations and to avoid any perception of trading on material non-public information. This filing represents a standard practice within the industry for managing executive compensation.

Comparison to Industry Standards

• Sell-to-cover transactions are standard practice across various industries for executives managing equity compensation, seen in companies ranging from technology giants like Apple and Microsoft to pharmaceutical firms.
• The use of a Rule 10b5-1 plan aligns with best corporate governance practices for managing insider transactions, providing transparency and mitigating concerns about opportunistic trading.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of shares, but as a routine, pre-planned transaction for tax purposes, it is unlikely to significantly impact shareholder sentiment or the company's valuation.
• Employees: No direct impact on general employees is indicated by this executive's stock transaction.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled sale by an executive to cover tax obligations on vested equity. Such transactions are common and generally not indicative of a change in management's confidence in the company's long-term prospects, especially when executed under a 10b5-1 plan. Therefore, it does not provide new information that would warrant a change in investment thesis, suggesting a 'hold' recommendation.

Keywords

Definium Therapeutics, DFTX, Mark Sullivan, Chief Legal Officer, Form 4, Insider Transaction, Stock Sale, Rule 10b5-1, Restricted Stock Units, Tax Obligations